ArticleMolecular medicine reports2017

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR‑FGFR1 fusion.

Xu-Hua Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.